| abstract |
FIELD: medicine; pharmaceuticals.SUBSTANCE: invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. In formula (I) P is hydrogen or group P, selected from following formulas: a) -C(=O)-P, b) -C(=OP, g) -C(=O)-O-P, h) -C(=O)-N(-K)(P), i) -C(=O)-O-L-O-P, l) -C(P)-O-C(=O)-P, m) -C(P)-O-C(=O)-O-P, v) -C(P)-P, y) -C(P)-N(-K)-C(=O)-O-P, z) -P(=O)(-P)(-P) and ab) -P, Ais CRR; Ais CRR; Ais CRR, S or O; each of Aindependently represents CRR; number of heteroatoms among atoms forming a ring, which consists of A, A, A, A, nitrogen atom adjacent to A, and a carbon atom adjacent to A, is 1 or 2; group represented by formularepresents a group represented by formula, values of other radicals are given in claim. Invention also relates to individual compounds.EFFECT: technical result is obtaining novel compounds of formula (I) inhibiting activity of cap-dependent endonuclease and which can be used in treating influenza virus.11 cl, 2 dwg, 40 tbl, 39 ex |